Study of efgartigimod for blistering skin diseases
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 or older if you have DEB, or 18 or older if you have EBA.
- You must have a confirmed diagnosis of DEB (with genetic testing) or EBA (with a skin biopsy).
- You must have antibodies against collagen VII in your blood.
- You must be able to care for yourself at least partially (Karnofsky score of 60% or higher).
- If you are of childbearing potential, you must agree to use contraception and have negative pregnancy tests.
- You must not have other blistering diseases like pemphigus or bullous pemphigoid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.